Product Description: Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Kumar D, et al. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1133-9.
CAS Number: 1174900-84-5
Molecular Weight: N/A
Compound Purity: 99.21
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: c-Met/HGFR